Newsroom
PRESS STATEMENT: ARHP SUPPORTS APPROVAL OF HPV VACCINE
Dr. Beth Jordan, Medical Director
Wayne C. Shields, President and CEO
Association of Reproductive Health Professionals (ARHP)
For Immediate Release
May 18, 2006
Contact:
Ann McCall
(202) 466-3825
communications@arhp.org
The Association of Reproductive Health Professionals (ARHP) urges the Food and Drug Administration (FDA) to approve the Human Papillomavirus (HPV) Recombinant Vaccine as part of a comprehensive approach to eradicating cervical cancer. With very few medically proven mechanisms to prevent cancer, the HPV vaccine represents a rare opportunity to prevent cervical cancer, which affects over 15,000 women in the United States each year.
The research demonstrates that this vaccine is both safe and effective in preventing the most dangerous strains of the cancer-causing and highly infectious HPV. The vaccine, along with appropriate screening (including Pap tests and DNA tests), are important measures toward the eventual eradication of cervical cancer through a combined approach: prevention and early detection.
Once approved, ARHP is committed to providing the necessary education surrounding this vaccine to health care providers, patients, and parents.
###
The Association of Reproductive Health Professionals (ARHP) is the leading
source for trusted medical education and information on reproductive and sexual
health. ARHP educates health care providers, informs consumers, and helps shape
public policy. ARHP is a non-profit membership association composed of highly
qualified and committed experts in reproductive health. ARHP members are health
professionals in clinical practice, education, research, and advocacy and they
include physicians, nurse practitioners, physician assistants, nurse midwives,
researchers, educators, pharmacists, and other professionals in reproductive
health. To learn more, visit: http://www.arhp.org.
|
